China's First Innovative Anti-HIV Drug to Present Keynote Report at Prestigious Western Scientific Conference! From October 15 to 18, 2025, the 20th EACS held at the Palais des Congrès de Paris. On October 16 at 14:10 local time, the latest 144-week SPRINT study results of Aidea Pharma’s Aitribond® as a switch therapy officially presented in an oral report during the "Forever Three-in-One" session.

Following its presentations at top-tier forums such as IAS 2025, Aitribond®—China’s first innovative single-tablet regimen (STR) for HIV—has again earned recognition on the global stage. This continued acclaim underscores Aidea Pharma's robust and persistent innovation as a leader in China's HIV treatment field.

Aitribond®: 144-Week Viral Suppression with Improved Cardiometabolic Profile

#MeP05.2: Long-term viral suppression, and cardiometabolic benefits of switch to ainuovirine coformulated with lamivudine, and tenofovir DF in virologically suppressed people with HIV-1: 144-week, open label results from the SPRINT post-study

The SPRINT study (Accelerated Switch to a Novel NNRTI), upon completing its 96-week extension phase, transitioned all eligible people living with HIV (PWH) into a real-world extension study, where they continued receiving Aitribond®.

Having now reached 192 weeks of follow-up, the study's 144-week data on virological suppression and cardiometabolic benefits presented. Findings indicate that after discontinuing traditional NNRTIs or boosted INSTI-based regimens, switching to Aitribond® enables PWH to maintain high rates of viral suppression long-term. The regimen also demonstrates a favorable safety profile, including sustained improvements in LDL-C levels and a reduction in Atherosclerotic Cardiovascular Disease (ASCVD) risk stratification [1]. The specific data formally disclosed at the congress.

7 Poster Presentations: Multi-Dimensional Clinical Value and Safety Benefits Across Diverse Populations

During this conference, Aidea Pharma also presented 7 additional poster displays, multi-dimensionally demonstrating the clinical value of Aitribond®. The research covers young and female PWH as well as those with NNRTI pre-existing resistance, showcasing the safety benefits of Aitribond® across multiple key dimensions including weight stability, lipid metabolism improvement, ASCVD risk reduction, and renal function stability.

Efficacy and Safety of Ainuovirine Fixed-Dose Combination in Young People Living with HIV-1 Infection: A Pooled Analysis from the RACER and SPRINT Studies (Two Randomized, Active-Controlled Phase 3 Trials).

#eP130: Efficacy, and safety of ainuovirine-based antiretroviral regimen in women with HIV-1: the pooled analysis of the RACER, and SPRINT studies, two multicenter, randomized, active controlled phase 3 trials

#eP149: High virologic suppression in treatment-naïve people with HIV-1 on ainuovirine- versus efavirenz-based antiretroviral regimen as initial therapy: effect of pretreatment NNRTI resistance from RACER trial, a multi-center, randomized, active-controlled study

#eP267: Improved atherosclerotic cardiovascular disease risk-associated dyslipidemia strata in people with HIV-1 switching to ainuovirine based antiretroviral regimen: week 144 results from SPRINT, a randomized phase 3 trial

#eP274: Long-term changes in triglyceride-glucose index and insulin resistance in virologically suppressed people with HIV-1 switching to ainuovirine coformulated with lamivudine, and tenofovir DF: 144-week, open-label results from the SPRINT post-study

#eP275: Long-term Lipid Metabolism Benefits of Switching to Ainuovirine based Regimen in People with HIV-1: 144-Week Results from the SPRINT Extensional Post-study

#eP285: Preserved renal function in PWH on ainuovirine-based antiretroviral regimen: week 144 results from SPRINT study, a randomized phase 3 trial